Moleculin Biotech is a clinical stage pharmaceutical company. Co.'s technologies include: Annamycin, an anthracycline designed to be different than existing approved anthracyclines by eliminating cardiotoxicity and avoiding the multidrug resistance mechanisms; WP1066 Portfolio, which includes WP1066 and WP1220, two of several Immune/Transcription Modulators in the portfolio designed to inhibit phosphorylated signal transducer and activator of transcription among other transcription factors associated with tumor activity, while also stimulating a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells.
|
Free MBRX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |